| DB ID | MyCo_3255 |
| Title | Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease |
| Year | 2011 |
| PMID | 21811868 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | Critically ill non-neutropenic patients |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The study was approved by the Ethics Committee, Hospital Universitario 12 de Octubre, Avenida de Córdoba s/n, Madrid, 28041, Spain |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | Over a period of 24 months (between June 2008 and May 2010) 965 patients were admitted to the ICU. Of these, 149 (15.4%) had a compatible clinical syndrome and host factors of IFD, and 98 (10.2%) met the criteria for inclusion (23 case patients in the IFD group and 75 patients in the control group without evidence of IFD. |
| Cohort No. | 23 Patients and 75 control |
| Age Group | 21-89 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad, Marnes la Coquette, France) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
